Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease.
Insulin-like growth factor 1 (IGF-1) serum levels have been reported to be altered in Alzheimer's disease patients, and it was suggested that the changes in IGF-1 serum level may play a role in disease pathology and progression. However, this notion remained controversial due to conflicting fin...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4881955?pdf=render |
| _version_ | 1818849481281503232 |
|---|---|
| author | Philip P Ostrowski Andrew Barszczyk Julia Forstenpointner Wenhua Zheng Zhong-Ping Feng |
| author_facet | Philip P Ostrowski Andrew Barszczyk Julia Forstenpointner Wenhua Zheng Zhong-Ping Feng |
| author_sort | Philip P Ostrowski |
| collection | DOAJ |
| description | Insulin-like growth factor 1 (IGF-1) serum levels have been reported to be altered in Alzheimer's disease patients, and it was suggested that the changes in IGF-1 serum level may play a role in disease pathology and progression. However, this notion remained controversial due to conflicting findings. We conducted a meta-analysis to determine the relationship between IGF-1 serum levels and Alzheimer's disease. We searched the databases PUBMED, Ovid SP, and Cochrane library for relevant studies. The primary data analyzed was serum IGF-1 from Alzheimer's disease subjects and controls. Pooled weighted mean difference using a random effects model was used to determine the relationship between serum levels and disease state. Nine studies were included in the meta-analysis compromising a total of 1639 subjects. The pooled weighted mean difference was -2.27ng/ml (95% CI: [-22.221, 17.66]) with a P value of 0.82. Thus our finding did not show clear relationship between low IGF-1 and Alzheimer's disease subjects. We did not find evidence of publication bias by analyzing a funnel plot as well as Egger's and Begg's tests. While eight out of the nine studies included in this meta-analysis detected a statistically significant increase or decrease in serum levels of IGF-1 in Alzheimer's disease subjects, the analysis as a whole did not show a significant trend in either direction. Thus, IGF-1 level is likely a critical personalized factor. A large database of clinical trials is required for better understanding the relationship between IGF-1 levels and Alzheimer's disease. |
| first_indexed | 2024-12-19T06:33:55Z |
| format | Article |
| id | doaj.art-fb283feac5f14e009cceaa4f3ca7ff35 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T06:33:55Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-fb283feac5f14e009cceaa4f3ca7ff352022-12-21T20:32:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015573310.1371/journal.pone.0155733Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease.Philip P OstrowskiAndrew BarszczykJulia ForstenpointnerWenhua ZhengZhong-Ping FengInsulin-like growth factor 1 (IGF-1) serum levels have been reported to be altered in Alzheimer's disease patients, and it was suggested that the changes in IGF-1 serum level may play a role in disease pathology and progression. However, this notion remained controversial due to conflicting findings. We conducted a meta-analysis to determine the relationship between IGF-1 serum levels and Alzheimer's disease. We searched the databases PUBMED, Ovid SP, and Cochrane library for relevant studies. The primary data analyzed was serum IGF-1 from Alzheimer's disease subjects and controls. Pooled weighted mean difference using a random effects model was used to determine the relationship between serum levels and disease state. Nine studies were included in the meta-analysis compromising a total of 1639 subjects. The pooled weighted mean difference was -2.27ng/ml (95% CI: [-22.221, 17.66]) with a P value of 0.82. Thus our finding did not show clear relationship between low IGF-1 and Alzheimer's disease subjects. We did not find evidence of publication bias by analyzing a funnel plot as well as Egger's and Begg's tests. While eight out of the nine studies included in this meta-analysis detected a statistically significant increase or decrease in serum levels of IGF-1 in Alzheimer's disease subjects, the analysis as a whole did not show a significant trend in either direction. Thus, IGF-1 level is likely a critical personalized factor. A large database of clinical trials is required for better understanding the relationship between IGF-1 levels and Alzheimer's disease.http://europepmc.org/articles/PMC4881955?pdf=render |
| spellingShingle | Philip P Ostrowski Andrew Barszczyk Julia Forstenpointner Wenhua Zheng Zhong-Ping Feng Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. PLoS ONE |
| title | Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. |
| title_full | Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. |
| title_fullStr | Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. |
| title_full_unstemmed | Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. |
| title_short | Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. |
| title_sort | meta analysis of serum insulin like growth factor 1 in alzheimer s disease |
| url | http://europepmc.org/articles/PMC4881955?pdf=render |
| work_keys_str_mv | AT philippostrowski metaanalysisofseruminsulinlikegrowthfactor1inalzheimersdisease AT andrewbarszczyk metaanalysisofseruminsulinlikegrowthfactor1inalzheimersdisease AT juliaforstenpointner metaanalysisofseruminsulinlikegrowthfactor1inalzheimersdisease AT wenhuazheng metaanalysisofseruminsulinlikegrowthfactor1inalzheimersdisease AT zhongpingfeng metaanalysisofseruminsulinlikegrowthfactor1inalzheimersdisease |